Next Article in Journal
Complex Assessment of X-ray Diffraction in Crystals with Face-Centered Silicon Carbide Lattice
Next Article in Special Issue
Synthesis and Structure Characterization of Three Pharmaceutical Compounds Based on Tinidazole
Previous Article in Journal
A Study of the Temperature-Dependent Surface and Upper Critical Magnetic Fields in KFeSe and LaSrCuO Superconductors
Previous Article in Special Issue
pH-Driven Polymorphic Behaviour of the Third PDZ Domain of PSD95: The Role of Electrostatic Interactions
 
 
Article
Peer-Review Record

Drug Release from Carrier Systems Comprising Meloxicam Crystals Formed by Impregnation-Evaporation

Crystals 2023, 13(3), 527; https://doi.org/10.3390/cryst13030527
by Petr Zámostný *, Michal Drahozal, Ondřej Švehla, Simona Römerová and Nikita Marinko
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Crystals 2023, 13(3), 527; https://doi.org/10.3390/cryst13030527
Submission received: 1 March 2023 / Revised: 15 March 2023 / Accepted: 16 March 2023 / Published: 19 March 2023

Round 1

Reviewer 1 Report

Please see the attachment

 

Comments for author File: Comments.pdf

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

In this manuscript, the authors reported impregnating a poorly water-soluble drug onto a hydrophilic carrier can improve dissolution properties. A method based on impregnation of a hydrophilic matrix by a hydrophobic poorly water-soluble drug was used to create coverage of the carrier surface by drug crystals, with the optimum preparation method used to produce volume impregnated granules for evaluation of dissolution performance and kinetics. The authors need to address some concerns before it is considered for publication.

1) The introduction should provide a concise overview of various strategies utilized to improve pharmaceutical solubility, including amorphous formulations, encapsulation materials, pharmaceutical salts, and pharmaceutical cocrystals.

Here are some references:

  • Doi: 10.1023/a:1007516718048 (amorphous formulations)
  • Doi: 10.3390/pharmaceutics14050979 (amorphous formulations)
  • Doi: 10.4103/2230-973X.96921 (encapsulation materials)
  • Doi: 10.1007/s40005-021-00540-0 (encapsulation materials)
  • Doi: 10.1021/acs.cgd.0c01197 (pharmaceutical salts)
  • Doi: 10.1002/open.202100246 (pharmaceutical salts)
  • Doi: 10.1007/s00289-019-02997-4 (pharmaceutical co-crystals)
  • Doi: 10.1021/acs.cgd.1c01408 (pharmaceutical co-crystals)

2) In the introduction, please also provide the solubility value of MX instead of just saying “low solubility”.

3) More references, especially, more up-to-date references should be included in the introduction.

4) Stability (both physical and chemical stability) test should also be conducted.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

All comments are well addressed, manuscript can be accepted for the publication

Back to TopTop